High-Impact Form 4 Intelligence
Real-time SEC insider trading data with advanced filtering. Free beta.
Total Buys (Filtered)
$25.0M
$24,999,970
Total Sells (Filtered)
$264K
$264,285
| Ticker | Company | Reporting Owner | Date | Value (USD) | Type | Form 4 |
|---|---|---|---|---|---|---|
|
LYEL
P
Lyell Immunopharma, Inc.
ARCH Venture Fund XIII, L.P.
• 10% Owner
Discretionary BuyΔOwn +52.0%
2026-03-06
$12,499,985MEGA
|
||||||
| LYEL |
Lyell Immunopharma, Inc.
|
10% Owner
Discretionary BuyΔOwn +52.0%
|
2026-03-06 | $12,499,985MEGA | P | Form 4 |
|
LYEL
P
Lyell Immunopharma, Inc.
ARCH Venture Partners IX, LLC
• 10% Owner
Discretionary BuyΔOwn +52.0%
2026-03-06
$12,499,985MEGA
|
||||||
| LYEL |
Lyell Immunopharma, Inc.
|
10% Owner
Discretionary BuyΔOwn +52.0%
|
2026-03-06 | $12,499,985MEGA | P | Form 4 |
| LYEL |
Lyell Immunopharma, Inc.
|
COO
Sell to Cover
|
2026-02-11 | $28,910 | S | Form 4 |
|
LYEL
S
Lyell Immunopharma, Inc.
Lee Gary K.
• Officer • Chief Scientific Officer
Sell to Cover
2026-02-11
$39,085
|
||||||
| LYEL |
Lyell Immunopharma, Inc.
|
Officer • Chief Scientific Officer
Sell to Cover
|
2026-02-11 | $39,085 | S | Form 4 |
| LYEL |
Lyell Immunopharma, Inc.
|
CEO
Sell to Cover
|
2026-02-11 | $174,372 | S | Form 4 |
|
LYEL
S
Lyell Immunopharma, Inc.
Bulis Veronica Sanchez
• Officer • VP, Corporate Controller
Sell to Cover
2026-02-10
$5,872
|
||||||
| LYEL |
Lyell Immunopharma, Inc.
|
Officer • VP, Corporate Controller
Sell to Cover
|
2026-02-10 | $5,872 | S | Form 4 |
| LYEL |
Lyell Immunopharma, Inc.
|
COO
Sell to Cover
|
2026-02-10 | $2,520 | S | Form 4 |
|
LYEL
S
Lyell Immunopharma, Inc.
Lee Gary K.
• Officer • Chief Scientific Officer
Sell to Cover
2026-02-10
$3,399
|
||||||
| LYEL |
Lyell Immunopharma, Inc.
|
Officer • Chief Scientific Officer
Sell to Cover
|
2026-02-10 | $3,399 | S | Form 4 |
| LYEL |
Lyell Immunopharma, Inc.
|
CEO
Sell to Cover
|
2026-02-10 | $10,127 | S | Form 4 |